Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0TPQUN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
9MW-2821
|
|||||
| Synonyms |
9MW 2821; 9MW-2821; 9MW2821
Click to Show/Hide
|
|||||
| Organization |
Jiangsu Maiweikang New Drug R & D Co., Ltd.; Mabwell (Shanghai) Bioscience Co., Ltd.
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Indication |
In total 2 Indication(s)
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Phase 2
Urothelial cancer [ICD11:2C9Z]
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Nectin-4 (NECTIN4)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Rebridge conjugation through reduced inter-chain cysteines.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.